Gilead Sciences

Live  

Gilead Sciences is an American biopharmaceutical company that focuses on the development and commercialization of innovative medicines for the treatment of life-threatening diseases. The company was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences is known for its groundbreaking work in the field of HIV/AIDS. In 1996, the company launched its first HIV medication, Viread, which was the first of its kind to be approved by the US Food and Drug Administration (FDA). Since then, Gilead has developed and commercialized other HIV medications, including Truvada, Atripla, and Biktarvy.
In addition to its work in HIV/AIDS, Gilead Sciences has expanded into other areas of medicine, including hepatitis C, liver diseases, and oncology. In 2017, the company acquired Kite Pharma, a leader in the development of personalized cancer therapies, further diversifying its portfolio.
Gilead Sciences has a global presence, with operations in North America, Europe, Asia, and Latin America. The company currently employs over 12,000 people worldwide and has a market capitalization of over $90 billion.
In recent years, Gilead Sciences has faced criticism for the high prices of its medications, particularly for its HIV and hepatitis C treatments. The company has implemented various initiatives to increase access to its medicines for patients in need, including partnerships with generic drug manufacturers and patient assistance programs.

R2lsZWFkIF NjaWVuY2Vz IGlzIGEgYm lvcGhhcm1h Y2V1dGljYW wgY29tcGFu eSB0aGF0IG lzIHBhcnRp Y3VsYXJseS Bub3RhYmxl IGZvciBzZX ZlcmFsIHJl YXNvbnMuIE ZpcnN0LCBp dCBoYXMgYS BzdHJvbmcg Zm9jdXMgb2 4gYW50aXZp cmFsIGRydW dzLCBlc3Bl Y2lhbGx5IH Rob3NlIHVz ZWQgdG8gdH JlYXQgaW5m ZWN0aW9ucy BsaWtlIEhJ Vi9BSURTLC BoZXBhdGl0 aXMgQiwgaG VwYXRpdGlz IEMsIGFuZC BpbmZsdWVu emEuIEdpbG VhZCBpcyB3 aWRlbHkgcm Vjb2duaXpl ZCBmb3IgaX RzIGRldmVs b3BtZW50IG 9mIHJldm9s dXRpb25hcn kgSElWIG1l ZGljYXRpb2 5zIGFuZCB0 cmVhdG1lbn RzIGZvciBo ZXBhdGl0aX MgQyB0aGF0 IGhhdmUgc2 lnbmlmaWNh bnRseSBpbX Byb3ZlZCBw YXRpZW50IG 91dGNvbWVz Ljxicj5Bbm 90aGVyIGFz cGVjdCB0aG F0IHNldHMg R2lsZWFkIG FwYXJ0IGlz IGl0cyBjb2 1taXRtZW50 IHRvIHJlc2 VhcmNoIGFu ZCBkZXZlbG 9wbWVudC4g VGhlIGNvbX BhbnkgaW52 ZXN0cyBoZW F2aWx5IGlu IHNjaWVudG lmaWMgaW5u b3ZhdGlvbi wgd2hpY2gg aGFzIGxlZC B0byB0aGUg ZGlzY292ZX J5IG9mIG5l dyB0aGVyYX BpZXMgYW5k IGVuaGFuY2 VtZW50IG9m IGV4aXN0aW 5nIHRyZWF0 bWVudHMuIF RoaXMgZm9j dXMgb24gUi ZhbXA7RCBo YXMgcG9zaX Rpb25lZCBH aWxlYWQgYX MgYSBsZWFk ZXIgaW4gdG hlIGJpb3Bo YXJtYWNldX RpY2FsIHNl Y3Rvci48Yn I+QWRkaXRp b25hbGx5LC BHaWxlYWQg aGFzIG1hZG UgaGVhZGxp bmVzIGZvci BpdHMgcm9s ZSBpbiBhZG RyZXNzaW5n IHB1YmxpYy BoZWFsdGgg Y3Jpc2VzLi BGb3IgZXhh bXBsZSwgZH VyaW5nIHRo ZSBDT1ZJRC 0xOSBwYW5k ZW1pYywgR2 lsZWFkIGRl dmVsb3BlZC ByZW1kZXNp dmlyLCBhbi BhbnRpdmly YWwgZHJ1Zy B0aGF0IGJl Y2FtZSBvbm Ugb2YgdGhl IGZpcnN0IH RyZWF0bWVu dHMgYXV0aG 9yaXplZCBm b3IgdXNlIG FnYWluc3Qg Q09WSUQtMT kuPGJyPlRo ZSBjb21wYW 554oCZcyBi dXNpbmVzcy Btb2RlbCBh bHNvIGluY2 x1ZGVzIGEg Y29tbWl0bW VudCB0byBh Y2Nlc3MgYW 5kIGFmZm9y ZGFiaWxpdH ksIHN0cml2 aW5nIHRvIH Byb3ZpZGUg aXRzIG1lZG ljYXRpb25z IHRvIHBhdG llbnRzIGFy b3VuZCB0aG Ugd29ybGQs IHBhcnRpY3 VsYXJseSBp biBsb3ctIG FuZCBtaWRk bGUtaW5jb2 1lIGNvdW50 cmllcy48Yn I+T3ZlcmFs bCwgR2lsZW FkIFNjaWVu Y2VzIGlzIG Rpc3Rpbmd1 aXNoZWQgYn kgaXRzIGlu bm92YXRpdm UgZHJ1ZyBk ZXZlbG9wbW VudCwgZm9j dXMgb24gY3 JpdGljYWwg dmlyYWwgaW 5mZWN0aW9u cywgYW5kIG l0cyByb2xl IGluIGFkZH Jlc3Npbmcg Z2xvYmFsIG hlYWx0aCBj aGFsbGVuZ2 VzLjxicj4=

VGhlIEdpbG VhZCBTY2ll bmNlcyBjb2 1wYW55J3Mg YnVzaW5lc3 MgbW9kZWwg aXMgZm9jdX NlZCBvbiBk ZXZlbG9waW 5nIGFuZCBj b21tZXJjaW FsaXppbmcg aW5ub3ZhdG l2ZSBtZWRp Y2luZXMgaW 4gYXJlYXMg b2YgaGlnaC B1bm1ldCBt ZWRpY2FsIG 5lZWQuIFRo aXMgaW5jbH VkZXMgY29u ZHVjdGluZy ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQgZm9yIH RyZWF0bWVu dHMgb2Ygdm lyYWwsIGxp dmVyLCBpbm ZsYW1tYXRp b24sIGFuZC BvbmNvbG9n eSBkaXNlYX Nlcy4gVGhl IGNvbXBhbn kgYWxzbyBz dHJpdmVzIH RvIGltcHJv dmUgYWNjZX NzIHRvIGl0 cyB0aGVyYX BpZXMgZm9y IHBhdGllbn RzIGFyb3Vu ZCB0aGUgd2 9ybGQsIHdo aWxlIG1haW 50YWluaW5n IGEgc3Ryb2 5nIGZpbmFu Y2lhbCBwZX Jmb3JtYW5j ZSBhbmQgZG VsaXZlcmlu ZyB2YWx1ZS B0byBpdHMg c2hhcmVob2 xkZXJzLiBH aWxlYWQncy BhcHByb2Fj aCBpbmNsdW RlcyBjb2xs YWJvcmF0aW 9ucyBhbmQg cGFydG5lcn NoaXBzIHdp dGggb3RoZX IgY29tcGFu aWVzLCBnb3 Zlcm5tZW50 IGFnZW5jaW VzLCBhbmQg bm9uLXByb2 ZpdCBvcmdh bml6YXRpb2 5zLCBhcyB3 ZWxsIGFzIG ludmVzdG1l bnRzIGluIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCB0byBkaX Njb3ZlciBh bmQgZGV2ZW xvcCBuZXcg dHJlYXRtZW 50cyBhbmQg ZXhwYW5kIH RoZSB1c2Ug b2YgaXRzIG V4aXN0aW5n IHByb2R1Y3 RzLg==

Gilead Sciences, like many companies, is affected by changes in interest rates in a few key ways regarding its earnings, cash flow, and valuation.
1. Cost of Borrowing: If interest rates rise, the cost of borrowing increases. Gilead, which may rely on debt for financing operations, acquisitions, or research and development, could face higher interest expenses. This could reduce net income and cash flow from operations.
2. Valuation Impact: Higher interest rates typically result in a higher discount rate used in discounted cash flow models. This can lead to a lower present value of expected future cash flows, thereby impacting the company’s market valuation negatively. Investors may also demand higher rates of return, further compressing the stock price.
3. Investment Decisions: Rising interest rates can lead to a tighter capital environment, potentially impacting Gilead’s ability to invest in new projects or research initiatives. Reduced investment could slow down growth and innovation, affecting long-term earnings potential.
4. Market Sentiment: The biotechnology and pharmaceutical sectors can be sensitive to macroeconomic conditions, including interest rates. If investors anticipate higher rates leading to economic slowdown, it may result in lower stock prices for companies like Gilead, as market sentiment shifts.
5. Cash Flow Management: Changes in interest rates can impact operating cash flows indirectly through shifts in consumer and business spending. If higher rates lead to economic contraction, this may affect sales of Gilead’s products, thus impacting cash flows.
In summary, Gilead Sciences’ earnings, cash flow, and valuation are moderately sensitive to changes in interest rates through borrowing costs, valuation methods, investment capacities, market sentiment, and overall economic conditions.

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvQz J6NWNNdGdW ek9UZkxzcG hRWEoud2Vi cCIgYWx0PS JHaWxlYWQg U2NpZW5jZX MiIHRpdGxl PSJHaWxlYW QgU2NpZW5j ZXMiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 OTAgd2lkdG g9OTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2ls ZWFkIFNjaW VuY2VzPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +TmCBDbGFp bSB5b3VyIG ZyZWUgZUJv b2s6IDxpPi JUaGUgQ2hl Y2tsaXN0IF ZhbHVlIElu dmVzdG9yIO KAlCBBIFNt YXJ0ZXIgV2 F5IHRvIFBp Y2sgU3RvY2 tzIjwvaT4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPC9wPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPCEtLQog ICAgICAgIC AgICAgICAg ICAgICAgIC A8ZGl2IHN0 eWxlPSdtYX JnaW4tdG9w OiAxMnB4Oy Bmb250LXNp emU6IDEzcH g7IGNvbG9y OiAjNDQ0Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BTaWduIHVw IG5vdyBhbm QgZ2V0IG91 ciBmcmVlIG VCb29rIAog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgPGI+ VGhlIENoZW NrbGlzdCBW YWx1ZSBJbn Zlc3RvciDi gJQgQSBTbW FydGVyIFdh eSB0byBQaW NrIFN0b2Nr czwvYj4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9kaXY+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IC0tPgogIC AgICAgICAg ICAgICAgIC AgICAgICA8 IS0tCiAgIC AgICAgICAg ICAgICAgIC AgICAgIDxk aXYgc3R5bG U9J21hcmdp bi10b3A6ID E2cHg7IGZv bnQtc2l6ZT ogMTRweDsg Y29sb3I6IC M0NDQ7IGZv bnQtZmFtaW x5OiAtYXBw bGUtc3lzdG VtLCBCbGlu a01hY1N5c3 RlbUZvbnQs IFNlZ29lIF VJLCBSb2Jv dG8sIEhlbH ZldGljYSBO ZXVlLCBzYW 5zLXNlcmlm OyBsaW5lLW hlaWdodDog MS42Oyc+Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICBIYX ZlIHlvdSBo ZWFyZCBhYm 91dCBvdXIg c2hvcnQgPH N0cm9uZyBz dHlsZT0nZm 9udC13ZWln aHQ6IDYwMD snPkRhaWx5 IFZpZGVvIE 5ld3NsZXR0 ZXI8L3N0cm 9uZz4/CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdodH RwczovL3d3 dy5pbnNpZ2 h0ZnVsdmFs dWUuY29tL2 5ld3NsZXR0 ZXIucGhwJy B0YXJnZXQ9 J19ibGFuay cgc3R5bGU9 J2NvbG9yOi AjMDA3QkZG OyB0ZXh0LW RlY29yYXRp b246IG5vbm U7IGZvbnQt d2VpZ2h0Oi A1MDA7IG1h cmdpbi1sZW Z0OiA2cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICBGaW 5kIG91dCBt b3JlCiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICA8L2E+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IDwvZGl2Pg ogICAgICAg ICAgICAgIC AgICAgICAg ICAtLT4KIC AgICAgICAg ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC A8L2Rpdj4K ICAgICAgIC AgICAgCiAg ICAgICAgCi AgICAgICAg PHNwYW4gY2 xhc3M9J2Js dXJyZWQtdG V4dCc+CiAg ICAgICAgIC AgIE1TNGdS MmxzWlcgRm tJRk5qYVdW dSBZMlZ6SU hkaGN5IEJt YjNWdVpHVm sgSUdsdUlE RTVPRCBjZ1 lua2dUV2xq IGFHRmxiQ0 JTYVcgOXla R0Z1TENCaC BJRzFsWkds allXIHdnWk c5amRHOXkg SUdaeWIyMG dUbSBWM0lG bHZjbXN1IE lGUm9aU0Jq YjIgMXdZVz U1SUhkaCBj eUJ1WVcxbF pDIEJoWm5S bGNpQjAgYU dVZ1ltbGli RyBsallXd2 diR0Z1IFpD QnZaaUJIYV cgeGxZV1Fz SUhkbyBhV0 5vSUhkaGN5 IEJyYm05M2 JpQm0gYjNJ Z2FYUnpJRy BobFlXeHBi bWNnIGNISn ZjR1Z5ZEcg bGxjeTQ4WW 5JKyBNaTRn UjJsc1pXIE ZrSUZOamFX VnUgWTJWek lHbHpJRyBF Z1ltbHZjR2 hoIGNtMWhZ MlYxZEcgbG pZV3dnWTI5 dCBjR0Z1ZV NCMGFHIEYw SUdadlkzVn ogWlhNZ2Iy NGdaRyBWMl pXeHZjR2x1 IFp5QmhibV FnWTIgOXRi V1Z5WTJsaC BiR2w2YVc1 bklIIFJvWl hKaGNHbGwg Y3lCbWIzSW diRyBsbVpT MTBhSEpsIF lYUmxibWx1 WnkgQmthWE 5sWVhObCBj eXdnZDJsMG FDIEJoSUhC aGNuUnAgWT NWc1lYSWda bSA5amRYTW diMjRnIFNF bFdMMEZKUk YgTXNJR2hs Y0dGMCBhWF JwY3lCQ0lH IEZ1WkNCRE xDQnMgYVha bGNpQmthWC BObFlYTmxj eXdnIGIyNW piMnh2WjMg a3NJR0Z1Wk NCeSBaWE53 YVhKaGRHID l5ZVNCa2FY TmwgWVhObG N5NDhZbiBJ K015NGdWR2 hsIElHTnZi WEJoYm4gbm lnSmx6SUda cCBjbk4wSU cxaGFtIDl5 SUdKeVpXRn IgZEdoeWIz Vm5hQyBCal lXMWxJR2x1 IElERTVPVF lnZDIgbDBh Q0IwYUdVZy BZWEJ3Y205 MllXIHdnYj JZZ2RHaGwg YVhJZ1NFbF dJSCBSeVpX RjBiV1Z1IG RDQmtjblZu TEMgQldhWE psWVdRcyBJ SGRvYVdOb0 lIIGRoY3lC MGFHVWcgWm 1seWMzUWdk SCBKbFlYUn RaVzUwIElI UnZJSFJoY2 0gZGxkQ0Jo YmlCbCBibn A1YldVZ1ky IEZzYkdWa0 lISmwgZG1W eWMyVWdkSC BKaGJuTmpj bWx3IGRHRn paU0IwYUcg RjBJR2x6SU dWeiBjMlZ1 ZEdsaGJDIE JtYjNJZ2RH aGwgSUhKbG NHeHBZMiBG MGFXOXVJRz ltIElIUm9a U0JJU1YgWW dkbWx5ZFhN dSBQR0p5UG pRdUlFIGx1 SURJd01URX MgSUVkcGJH VmhaQyBCVF kybGxibU5s IGN5QmhZM0 YxYVggSmxa Q0IwYUdVZy BZbWx2Y0do aGNtIDFoWT JWMWRHbGog WVd3Z1kyOX RjRyBGdWVT d2dVR2hoIG NtMWhjM05s ZEMgd2dabT l5SUNReCBN U0JpYVd4c2 FXIDl1TGlC VWFHbHogSU dGamNYVnBj MiBsMGFXOX VJR0p5IGIz Vm5hSFFnUj IgbHNaV0Zr SUhSbyBaU0 JpYkc5amEy IEoxYzNSbG NpQmsgY25W bkxDQlRiMy BaaGJHUnBM Q0IzIGFHbG phQ0J5Wlgg WnZiSFYwYV c5dSBhWHBs WkNCMGFHIF VnZEhKbFlY UnQgWlc1ME lHWnZjaSBC b1pYQmhkR2 wwIGFYTWdR eTQ4WW4gSS tOUzRnUjJs cyBaV0ZrSU ZOamFXIFZ1 WTJWeklHaG ggY3lCaElI TjBjbSA5dV p5QmpiMjF0 IGFYUnRaVz UwSUggUnZJ R052Y25Cdi BjbUYwWlNC emIyIE5wWV d3Z2NtVnog Y0c5dWMybG lhVyB4cGRI a3VJRlJvIF pTQmpiMjF3 WVcgNTVJR2 hoY3lCayBa WFpsYkc5d1 pXIFFnWVc0 Z1lXTmogWl hOeklIQnli MiBkeVlXMG dkRzhnIGNI SnZkbWxrWl MgQnBkSE1n YldWayBhV0 5oZEdsdmJu IE1nZEc4Z2 JHOTMgTFds dVkyOXRaUy BCamIzVnVk SEpwIFpYTW dZWFFnWkcg bHpZMjkxYm 5SbCBaQ0J3 Y21salpYIE 1zSUdGdVpD QmggYkhOdk lHaGhjeSBC d2NtOW5jbU Z0IGN5QjBi eUJ6ZFggQn diM0owSUdO diBiVzExYm 1sMGVTIEJo Ym1RZ1pXUj EgWTJGMGFX OXVZVyB3Z2 FXNXBkR2xo IGRHbDJaWE 11UEcgSnlQ all1SUVsdS BJREl3TWpB c0lFIGRwYk dWaFpDQlQg WTJsbGJtTm xjeSBCdFlX UmxJR2hsIF lXUnNhVzVs Y3kgQjNhWF JvSUdsMCBj eUJsZUhCbG NtIGx0Wlc1 MFlXd2cgWk hKMVp5d2dj bSBWdFpHVn phWFpwIGNp d2dkMmhwWT IgZ2djMmh2 ZDJWayBJSE J5YjIxcGMy IGx1WnlCeV pYTjEgYkhS eklHbHVJSC BSeVpXRjBh VzVuIElFTl BWa2xFTFQg RTVJSEJoZE dsbCBiblJ6 TGlCVWFHIF VnWkhKMVp5 QnkgWldObG FYWmxaQyBC bGJXVnlaMl Z1IFkza2dk WE5sSUcgRj FkR2h2Y21s NiBZWFJwYj I0Z1puIEp2 YlNCMGFHVW cgUmtSQklH RnVaQyBCb1 lYTWdjMmx1 IFkyVWdZbV ZsYmkgQmth WE4wY21saS BkWFJsWkNC aGNtIDkxYm 1RZ2RHaGwg SUhkdmNteG tMaiB4aWNq NDNMaUJIIG FXeGxZV1Fn VTIgTnBaVz VqWlhNZyBh R0Z6SUdFZ1 pHIGwyWlhK elpTQjMgYj NKclptOXlZ MiBVc0lIZH BkR2dnIFpX MXdiRzk1Wl cgVnpJR1p5 YjIwZyBiM1 psY2lBMk5T IEJqYjNWdW RISnAgWlhN Z1lXNWtJRy BFZ2JHVmha R1Z5IGMyaH BjQ0IwWlcg RnRJRzFoWk dVZyBkWEFn YjJZZ05EIG NsSUhkdmJX VnUgTGp4aW NqNDRMaSBC VWFHVWdZMj l0IGNHRnVl U0JvWVggTW dZU0J6ZEhK diBibWNnWj J4dlltIEZz SUhCeVpYTm wgYm1ObExD QjNhWCBSb0 lHOXdaWEpo IGRHbHZibk 1nYVcgNGdU bTl5ZEdnZy BRVzFsY21s allTIHdnUl hWeWIzQmwg TENCS1lYQm hiaSB3Z1lX NWtJRUZ6IG FXRWdVR0Zq YVcgWnBZeT Q4WW5JKyBP UzRnUjJsc1 pXIEZrSUZO amFXVnUgWT JWeklHaGhj eSBCaVpXVn VJRzVoIGJX VmtJRzl1Wl MgQnZaaUIw YUdVZyBWMj l5YkdUaWdK IGx6SUUxdm MzUWcgUVdS dGFYSmxaQy BCRGIyMXdZ VzVwIFpYTW dZbmtnUm0g OXlkSFZ1Wl NCTiBZV2Ro ZW1sdVpTIE JtYjNJZ1pt OTEgY2lCam IyNXpaVyBO MWRHbDJaU0 I1IFpXRnlj eUFvTWogQX hOeTB5TURJ dyBLUzQ4WW 5JK01UIEF1 SUVkcGJHVm ggWkNCVFky bGxibSBObG N5QnBjeUJq IGIyMXRhWF IwWlcgUWdk RzhnYzNWei BkR0ZwYm1G aWFXIHhwZE hrZ1lXNWsg SUdoaGN5Qn paWCBRZ2RH RnlaMlYwIG N5QjBieUJ5 WlcgUjFZMl VnZEdobCBh WElnWlc1Mm FYIEp2Ym0x bGJuUmggYk NCcGJYQmhZ MyBRc0lHbH VZMngxIFpH bHVaeUJoSU cgZHZZV3dn ZEc4ZyBjMj kxY21ObElE IEV3TUNVZ2 NtVnUgWlhk aFlteGxJRy BWc1pXTjBj bWxqIGFYUj VJR0o1SUQg SXdNakFnWV c1ayBJSEps WkhWalpTIE JuY21WbGJt aHYgZFhObE lHZGhjeSBC bGJXbHpjMm x2IGJuTWdZ bmtnTWogVW xJR0o1SURJ dyBNakl1Ci AgICAgICAg PC9zcGFuPg ogICAgICAg IAogICAgIC AgIA==
See Company Q&A